Navigation Links
Kevin McHale Instrumental in Forming the 'Help Me Hear Foundation'
Date:8/19/2007

SAINT PAUL, Minn., Aug. 15 /PRNewswire-USNewswire/ -- Kevin McHale is one of five board members to start the Help Me Hear Foundation ("HMH"), a non-profit organization incorporated in Saint Paul, Minnesota. McHale will also act as the spokesperson. HMH was created to gift cochlear implants to impoverished deaf children who would otherwise never be able to obtain one. Dr. William House, the "true" inventor of the cochlear implant, also sits on the Board of Directors.

While the burden of deafness on an individual of any age is substantial, the burden on infants and developing children is debilitating. The first three years of life are considered the "critical period" of normal speech development. Children who cannot hear sounds during this critical period experience deficits in speech development and academic achievement.

A deaf child who is given a cochlear implant is given the opportunity to hear sounds, which in turn, affords them the opportunity to learn how to communicate orally just as a hearing child does. Being able to communicate orally with the hearing world will allow these deaf children a chance to lead a "normal" life. In fact, most people who meet a 10 year old child who was given a cochlear implant at age 1 or 1 1/2, would likely be surprised to learn the child was born deaf.

In the United States, the real cost of a cochlear implant, required implant surgery, and follow-up rehab, ranges from $50,000 to $100,000. HMH, however, will buy a cochlear implant, locate an experienced surgeon willing to donate services, and coordinate the needed follow-up therapy all for just $7,000 per child.

Because of the prohibitive cost, it is estimated that only 1% of the world's deaf population will ever receive a cochlear implant. HMH hopes to change that statistic by raising funds to provide impoverished deaf children with cochlear implants.

When asked why he supports such an organization McHale responded, "Because every child d
'/>"/>

SOURCE HELP ME HEAR FOUNDATION

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Rapid Flu Tests May Prove Especially Helpful This Season
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
6. Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show
7. NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking
8. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary ... , “Alive Inside” shadows a social worker who advocates for the use of music ... about bringing music to residents in health care centers who may have lost a ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State Urology is celebrating ... of a merger of five of the busiest urology practices in Morris County. ... cost-effective and higher quality care than they did individually. Their mission statement ...
(Date:8/31/2015)... ... ... Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an “NJ ... Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters in ... year. He was inducted into the National Honor Society as a sophomore, was an ...
(Date:8/31/2015)... Nashville, TN (PRWEB) , ... August 31, 2015 , ... ... and how it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye ... is the most common cause of visual impairment among children, affecting approximately 2 to ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... The College of Optometrists in Vision,Development (COVD) ... O.D., FCOVD, was installed as its 29th president ... Meeting held on,October 20. Dr. Fortenbacher, 53, who ... for eight years, assumes the new role and ...
... Nov. 2 Addressing more than,100 cardiologists and ... chairman and CEO, set out four critical priorities ... today at,Schering-Plough,s fourth annual Cardiovascular Summit in advance ... In his speech, Hassan emphasized the potential ...
... 2 This week in Washington,experts and activists on ... Yoweri Museveni, acting on concerns raised by a number ... the US,to give a speech on AIDS policy, sponsored ... President Bush., "Ugandans deserve respect and recognition for ...
... But most humans couldn,t maintain such a low-cal diet, ... Cutting back drastically on daily calorie intake can lead ... at Buffalo researchers. , They speculate that this kind ... age, slowing the progression to disability. , A lifelong ...
... 2 Shoot For a Cure, the 15th anniversary,celebration ... Hospital, will be held at 6 p.m. Thursday, Nov. ... This year,s celebration will honor Bloomfield resident Penny B.,Blumenstein, ... System. The evening will include an auction, dinner ...
... Nov. 2 ABR-Affinity,BioReagents, a leading global antibody manufacturer, ... Society for,Neuroscience Meeting in San Diego, California, November 3 ... past week and a half, the influx of meeting,participants ... hard hit,economy of the region. "All of the staff ...
Cached Medicine News:Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 2Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 3Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:President Museveni's Visit Protested by HIV/AIDS Experts 2Health News:Calorie-Starved Rats Live Longer: Study 2Health News:ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: